Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Mar;58(1):3-12.
doi: 10.20471/acc.2019.58.01.01.

ADAPTATION AND VALIDATION OF THE CAMBRIDGE PULMONARY HYPERTENSION OUTCOME REVIEW (CAMPHOR) FOR CROATIA

Ana Hećimović  1 , Alice Heaney  1 , Stephen P McKenna  1 , Latinka Basara  1 , Marko Jakopović  1 , Andrea Vukić Dugac  1 , Gzim Redžepi  1 , Cecilija Rotim  1 , Miroslav Samaržija  1 , Nataša Jokić-Begić  1 , Sanja Popović-Grle  1
Affiliations

ADAPTATION AND VALIDATION OF THE CAMBRIDGE PULMONARY HYPERTENSION OUTCOME REVIEW (CAMPHOR) FOR CROATIA

Ana Hećimović et al. Acta Clin Croat. 2019 Mar.

Abstract

Pulmonary hypertension (PH) is a chronic disease which severely impairs quality of life (QoL). The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) is the first disease-specific tool to assess patient-reported symptoms, functioning and QoL in PH patients. The aim of this study was to adapt and validate the CAMPHOR for use in Croatia. The adaptation process involved three stages: translation (bilingual and lay panel), cognitive debriefing interviews with patients and psychometric validation. For the latter stage, a postal survey was conducted with 50 patients to examine the reliability and validity of the adapted scale. All three scales of the Croatian CAMPHOR demonstrated excellent internal consistency (Symptoms = 0.93; Activity limitations = 0.94; QoL = 0.92) and test-retest reliability correlations (Symptoms = 0.90; Activity limitations = 0.95; QoL = 0.90). Predicted correlations with the SF-36 scales provided evidence for construct validity of the CAMPHOR scales. Evidence for known group validity was shown by the ability of the scales to distinguish between participants based on patient-perceived general health and disease severity. The Croatian version of the CAMPHOR is a valid and reliable tool for use in clinical routine and clinical research.

Keywords: Croatia; Hypertension, pulmonary; Quality of life; Reproducibility of results; Surveys and questionnaires.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Median CAMPHOR scale scores by perceived disease severity. All comparisons statistically significant (p<0.01; 2-tailed); QoL = quality of life
Fig. 2
Fig. 2
Median CAMPHOR scale scores by perceived general health. All comparisons statistically significant (p<0.001; 2-tailed); QoL = quality of life
See this image and copyright information in PMC

References

    1. Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed Association for European Paediatric and Congenital Cardiology (AEPC), International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67–119. 10.1093/eurheartj/ehv317 - DOI - PubMed
    1. Galiè N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J. 2004;25:2243–78. 10.1016/j.ehj.2004.09.014 - DOI - PubMed
    1. Humbert M, Lau EM, Montani D, Jaïs X, Sitbon O, Simonneau G. Advances in therapeutic interventions for patients with pulmonary arterial hypertension. Circulation. 2014;130:2189–208. 10.1161/CIRCULATIONAHA.114.006974 - DOI - PubMed
    1. McLaughlin VV, Badesch DB, Delcroix M, Fleming TR, Gaine SP, Galiè N, et al. End points and clinical trial design in pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54:S97–107. 10.1016/j.jacc.2009.04.007 - DOI - PubMed
    1. Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010;122:164–72. 10.1161/CIRCULATIONAHA.109.898122 - DOI - PubMed

Publication types

LinkOut - more resources